Explore

Rapid Read Rapid Read
Research Explores Transcription Factors' Role in Adaptive Immunity and Cancer

Research Explores Transcription Factors' Role in Adaptive Immunity and Cancer

New research is focusing on the role of transcription factors in regulating adaptive immunity, particularly in the context of cancer and autoimmune diseases. This area of study, detailed in 'Transcription Factors as Regulators of Adaptive Immunity - Volume II,' investigates how these factors influence the development, activation, migration, and effector functions of adaptive immune cells like T and B lymphocytes and antigen-presenting cells (APCs). The research aims to understand the precise changes in gene expression orchestrated by transcription factors binding to cis-regulatory elements in the genome. This includes exploring their impact on immune dysregulation and human diseases, with a specific interest in how these mechanisms relate to cancer. The scope of this research emphasizes experimental validation over purely bioinformatic analyses, especially when applying genetic analyses to oncological diseases, requiring real laboratory and clinical data.
Rapid Read Rapid Read
COVID-19 Vaccine May Offer Survival Benefit to Brain Cancer Patients, Preliminary Study Suggests

COVID-19 Vaccine May Offer Survival Benefit to Brain Cancer Patients, Preliminary Study Suggests

A preliminary study, not yet peer-reviewed, suggests that the COVID-19 vaccine might improve survival rates for patients with glioblastoma, an aggressive form of brain cancer. Patients who received the COVID-19 vaccine within 100 days before a biopsy or tumor surgery lived twice as long as unvaccinated patients. Specifically, vaccinated patients lived 743 days or longer, compared to 349 days for unvaccinated patients. This association was observed only with COVID-19 vaccines, not with other non-mRNA vaccines like those for flu or pneumonia. James Markert, a neurosurgeon at the University of Alabama at Birmingham, noted that while the study found an association, it does not establish a cause-and-effect relationship. Elias Sayour, a pediatric oncologist at the University of Florida College of Medicine, who was not involved in this specific study, highlighted mounting evidence that mRNA COVID-19 vaccines may stimulate anti-cancer activity. His previous research linked mRNA COVID-19 vaccination to extended sur...
Reuters Reuters
Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines

Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.
Rapid Read Rapid Read
Nanoplatelets Show Promise as Targeted Drug Delivery System for Cancer Therapy

Nanoplatelets Show Promise as Targeted Drug Delivery System for Cancer Therapy

Researchers have developed a novel nanoplatelet platform that could significantly advance targeted radionuclide therapy (TRT) for cancer. TRT involves attaching radioisotopes to molecules that specifically target cancer cells. The new nanoplatelet, created through a unique assembly process, possesses a specialized layered structure that allows it to rapidly absorb and strongly bind a wide variety of radioisotopes. This innovation addresses the challenge of effectively delivering short-lived radioactive isotopes to tumor sites, which are crucial for both imaging tumors and inflicting cellular damage. The platform is versatile, accommodating numerous radioisotopes, including those previously unstudied, and offers potential for both imaging and therapeutic applications, or a dual theranostic approach.
Rapid Read Rapid Read
New CAR-T Cell Therapy Technique Shows Promise Against Solid Tumors

New CAR-T Cell Therapy Technique Shows Promise Against Solid Tumors

Researchers at the USC Viterbi School of Engineering have developed a new technique, called SHIFTERS, to enhance CAR-T cell therapy's effectiveness against solid tumors. CAR-T cell therapy, a significant advancement in cancer treatment, has primarily been successful against blood cancers. The challenge with solid tumors has been the lack of a consistent, clear target for CAR-T cells. The SHIFTERS approach addresses this by using focused ultrasound in conjunction with a tumor's low oxygen levels to induce tumor cells to temporarily display the CD19 marker, which CAR-T cells recognize. This two-tiered attack ensures that the marker is only displayed where both signals (low oxygen and focused ultrasound) meet, directing CAR-T cells precisely to the tumor. Initial testing on lab-grown cancer cells, tumor models, and animals demonstrated that this method significantly strengthened CAR-T cell attacks, leading to dramatic tumor shrinkage. Notably, only 10 to 25 percent of tumor cells needed to display the tempora...
Trendline Trendline
Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment

Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment

Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment
Trendline Trendline
Oncolytics Biotech Receives FDA Alignment for Accelerated Approval Pathway of Pelareorep in Colorectal Cancer

Oncolytics Biotech Receives FDA Alignment for Accelerated Approval Pathway of Pelareorep in Colorectal Cancer

Oncolytics Biotech Receives FDA Alignment for Accelerated Approval Pathway of Pelareorep in Colorectal Cancer
Rapid Read Rapid Read
Korean Research Team Develops Microfluidic Chip for Personalized Glioblastoma Treatment Prediction

Korean Research Team Develops Microfluidic Chip for Personalized Glioblastoma Treatment Prediction

A Korean research team has developed a microfluidic chip designed to predict personalized treatment responses for glioblastoma patients. This innovative chip recreates a patient's own tumor cells along with the surrounding peritumoral vascular environment, known as the blood–brain tumor barrier (BBTB). Glioblastoma is a highly aggressive brain tumor, challenging to treat due to rapid cancer cell spread and patient-specific tumor characteristics. The brain's natural blood–brain barrier typically blocks harmful substances, but it also impedes anticancer drugs from reaching tumors. In glioblastoma, this vascular barrier changes, and the extent of this change varies among patients, influencing drug efficacy. Traditional treatment response predictions rely on genetic information and biomarkers, which do not account for these patient-specific vascular environments. The new chip addresses this by co-culturing patient-derived glioblastoma cells with brain vascular endothelial cells and astrocytes, precisely mimick...
Rapid Read Rapid Read
St. Jude Children’s Research Hospital Appoints Charles W.M. Roberts as New President and CEO

St. Jude Children’s Research Hospital Appoints Charles W.M. Roberts as New President and CEO

St. Jude Children’s Research Hospital has announced the appointment of Charles W.M. Roberts, MD, PhD, as its new president and CEO. Dr. Roberts, who joined St. Jude in 2015 as the Comprehensive Cancer Center director, will succeed James R. Downing, MD, who is stepping down as part of a planned leadership transition. During his tenure as Cancer Center director, Roberts led the center to achieve the top “Exceptional” ranking by the National Cancer Institute in both reviews and its best score in institutional history each time. His research has made significant advancements in cancer epigenetics, particularly in uncovering tumor-suppressive roles of SMARCAB1/SNF5 in lethal pediatric rhabdoid tumors, leading to new FDA-approved and investigational cancer therapies for both children and adults. Dr. Roberts' contributions have been recognized by the medical and scientific community, including his election as a fellow of the American Association for Cancer Research (AACR) Academy.
Rapid Read Rapid Read
Henrietta Lacks' HeLa Cells Continue to Impact Medical Research Decades After Her Death

Henrietta Lacks' HeLa Cells Continue to Impact Medical Research Decades After Her Death

Henrietta Lacks, an African-American woman who died in 1951 at the age of 31, has had an unparalleled impact on medical science through her 'immortal' HeLa cells. These cells were taken from her tumor during her cervical cancer treatment at Johns Hopkins Hospital without her knowledge or consent, a common practice at the time. Unlike other human cells, HeLa cells continued to grow and divide indefinitely in laboratory conditions, becoming the first continuously cultured human cell line. This discovery provided scientists with an invaluable tool for research, leading to significant breakthroughs. The cells were instrumental in developing the polio vaccine and have been used extensively to study cancer, viruses, the effects of radiation, in-vitro fertilization, cloning, and gene mapping. The scale of their use is vast, with nearly 11,000 patents involving HeLa cells documented at the time of a 2011 review.
Rapid Read Rapid Read
Maternal Genes Implicated in Trophoblastic Tumor Relapse Post-Immunotherapy

Maternal Genes Implicated in Trophoblastic Tumor Relapse Post-Immunotherapy

Recent research indicates that cancer cells in placental site trophoblastic tumors (PSTTs) can acquire uninherited maternal genes, potentially leading to tumor relapse after immunotherapy. This finding, reported by Kyosuke Kagami of Kanazawa University and colleagues, suggests a novel mechanism of tumor adaptation through intercellular DNA transfer. Unlike normal placental situations where material exchange between mother and child is highly selective, PSTT cancer cells appear to incorporate functional genetic material from surrounding cells. Whole-genomic sequencing results point to cell-cell fusion as a possible method for this acquisition. The acquired maternal genes enable PSTT cancer cells to produce the antibody immunoglobulin, which explains the clinical observation of renal antibody accumulation in these patients. This research highlights a new route for tumor adaptation, particularly in the context of cancer relapse following immunotherapy.
Rapid Read Rapid Read
Infinitopes Initiates First Clinical Trial for Precision Therapeutic Cancer Vaccine ITOP1 in Oesophageal Cancer

Infinitopes Initiates First Clinical Trial for Precision Therapeutic Cancer Vaccine ITOP1 in Oesophageal Cancer

Infinitopes has announced the dosing of the first patient with ITOP1, its lead investigational therapeutic cancer vaccine candidate. This marks the initial clinical evaluation of Infinitopes’ Precision Immunomics platform, which integrates large-scale immunopeptidomic antigen discovery with engineered viral vector technologies. The platform aims to identify naturally presented tumor antigens capable of generating durable anti-tumor T-cell responses. The VISTA study (Vaccination with ITOP1 in resectable oesophageal adenocarcinoma to evaluate Safety, Tolerability and Anti-tumour activity) is a Phase I/IIa clinical trial conducted in collaboration with the University of Oxford. This study will assess ITOP1 in patients with newly diagnosed, surgically resectable oesophageal and gastro-oesophageal junction adenocarcinoma (OAC). Unlike post-surgery vaccination approaches, VISTA investigates early treatment while the primary tumor remains in situ, aiming to generate stronger anti-tumor T-cell responses alongside ...